search
Back to results

Moderate to Persistent Asthma in the Obese Subject

Primary Purpose

Asthma

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Montelukast
Sugar pill
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Asthma

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • moderate persistent asthma as defined daily symptoms, nocturnal awakenings >1 time/week but not daily, daily short-acting beta agonist usage
  • pre-bronchodilator Force expiratory volume (FEV1)>55% but <90%.
  • Subjects must be on controller therapy for asthma with ICS for at least one month prior to enrollment.
  • methacholine testing that causes a drop in the FEV1 of 20% (8mg/ml off ICS or 16mg/ml) on ICS within 6 months prior to entry
  • physician diagnosis of asthma for at least one year prior to study enrollment.
  • Obesity defined as BMI greater than 30.
  • subjects must have an Asthma Control Questionnaire (ACQ) score >1.25 on the Juniper Asthma Control Questionnaire (indicating poor asthma control),
  • require daily medications for asthma and be compliant with study related medications.

Exclusion Criteria:

  • Subjects must not have been intubated in the last 5 years or unstable asthma symptoms resulting in significant loss or work or school
  • upper or lower respiratory tract infection within 1 month of the study
  • use of antibiotics within 4 weeks of the study
  • use of oral glucocorticoids within 4 weeks
  • use of theophylline
  • smoking history greater than 10 pack years or any cigarette use within the past two years
  • significant non-asthma pulmonary disease or other medical problems
  • Subjects planning to undergo gastric bypass surgery within 4 months of the enrollment date will be excluded since weight loss is a potential confounder of asthma control
  • Pregnant women will also be excluded

Sites / Locations

  • Duke Asthma Allergy and Airway Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

leukotriene receptor antagonist (LTRA) montelukast

Sugar Pill

Arm Description

Montelukast (LTRA) administered with moderate dose of inhaled steroid

High dose of inhaled steroid administered with sugar pill

Outcomes

Primary Outcome Measures

Determine the Effect of Montelukast / Moderate Dose ICS Versus High Dose ICS on Asthma Control as Measured by the Asthma Control Questionnaire.

Secondary Outcome Measures

Serum Adiponectin, Leptin, Tumor Necrosis Alpha (TNF-α) and Interleukin 6 (IL6) Levels
Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Change in Trends in Asthma Control Questionnaire (ACQ ACTQ) Scores Over Duration of the Study
Asthma Exacerbation
Asthma exacerbation is defined as the development of an increase in asthma symptoms which results in an increase in the use of asthma medications (typically inhaled corticosteroids and/or parenteral corticosteroids) or the addition of another new asthma medication or antibiotics.
Sputum Cell Counts and Differentials

Full Information

First Posted
October 19, 2009
Last Updated
November 7, 2014
Sponsor
Duke University
search

1. Study Identification

Unique Protocol Identification Number
NCT01016847
Brief Title
Moderate to Persistent Asthma in the Obese Subject
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Cross-over Study to Evaluate the Effect of the Leukotriene Antagonist (Singulair©) Plus Moderate Dose Beclomethasone Compared to High Dose Beclomethasone in Obese Subjects With Moderate Persistent Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
December 2012
Overall Recruitment Status
Terminated
Why Stopped
Unable to enroll enough study subjects. Study has been terminated
Study Start Date
January 2010 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
November 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Obesity is associated with increased airway inflammation and asthma severity that results in suboptimal control of asthma despite therapy with high dose inhaled corticosteroids (ICS). The investigators suggested that the addition of Singular (montelukast)[LTRA] to moderate doses of inhaled corticosteroids will improve asthma control. This cross over study will be treat subjects with moderate dose ICS/LTRA for 12 weeks and high dose ICS with placebo for 12 weeks.
Detailed Description
Subjects will enter the 2-week run-in period after meeting eligibility criteria at the screening visit (visit 1). During run-in subjects will have all usual asthma medications discontinued and will be placed on inhaled corticosteroids at moderate doses and leukotriene receptor antagonists will be withdrawn (LTRA wash-out). Subjects will be monitored to rule out any acute infection or symptoms consistent with an exacerbation. The run-in period will be used to assess subject compliance and understanding of study related procedures. Following the run-in, to be eligible for the randomization subjects must have an ACQ score >1.25 on the Juniper Asthma Control Questionnaire.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
38 (Actual)

8. Arms, Groups, and Interventions

Arm Title
leukotriene receptor antagonist (LTRA) montelukast
Arm Type
Active Comparator
Arm Description
Montelukast (LTRA) administered with moderate dose of inhaled steroid
Arm Title
Sugar Pill
Arm Type
Placebo Comparator
Arm Description
High dose of inhaled steroid administered with sugar pill
Intervention Type
Drug
Intervention Name(s)
Montelukast
Intervention Description
10 mg Q day
Intervention Type
Other
Intervention Name(s)
Sugar pill
Intervention Description
Sugar pill that looks like Montelukast that will be given Q day
Primary Outcome Measure Information:
Title
Determine the Effect of Montelukast / Moderate Dose ICS Versus High Dose ICS on Asthma Control as Measured by the Asthma Control Questionnaire.
Time Frame
Baseline/randomization to week 16
Secondary Outcome Measure Information:
Title
Serum Adiponectin, Leptin, Tumor Necrosis Alpha (TNF-α) and Interleukin 6 (IL6) Levels
Time Frame
Baseline/randomization to week 16
Title
Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Time Frame
Baseline/randomization to week 16
Title
Change in Trends in Asthma Control Questionnaire (ACQ ACTQ) Scores Over Duration of the Study
Time Frame
Baseline/randomization to week 16
Title
Asthma Exacerbation
Description
Asthma exacerbation is defined as the development of an increase in asthma symptoms which results in an increase in the use of asthma medications (typically inhaled corticosteroids and/or parenteral corticosteroids) or the addition of another new asthma medication or antibiotics.
Time Frame
Baseline/randomization to week 16
Title
Sputum Cell Counts and Differentials
Time Frame
Baseline/randomization to week 16

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: moderate persistent asthma as defined daily symptoms, nocturnal awakenings >1 time/week but not daily, daily short-acting beta agonist usage pre-bronchodilator Force expiratory volume (FEV1)>55% but <90%. Subjects must be on controller therapy for asthma with ICS for at least one month prior to enrollment. methacholine testing that causes a drop in the FEV1 of 20% (8mg/ml off ICS or 16mg/ml) on ICS within 6 months prior to entry physician diagnosis of asthma for at least one year prior to study enrollment. Obesity defined as BMI greater than 30. subjects must have an Asthma Control Questionnaire (ACQ) score >1.25 on the Juniper Asthma Control Questionnaire (indicating poor asthma control), require daily medications for asthma and be compliant with study related medications. Exclusion Criteria: Subjects must not have been intubated in the last 5 years or unstable asthma symptoms resulting in significant loss or work or school upper or lower respiratory tract infection within 1 month of the study use of antibiotics within 4 weeks of the study use of oral glucocorticoids within 4 weeks use of theophylline smoking history greater than 10 pack years or any cigarette use within the past two years significant non-asthma pulmonary disease or other medical problems Subjects planning to undergo gastric bypass surgery within 4 months of the enrollment date will be excluded since weight loss is a potential confounder of asthma control Pregnant women will also be excluded
Facility Information:
Facility Name
Duke Asthma Allergy and Airway Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27704
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Moderate to Persistent Asthma in the Obese Subject

We'll reach out to this number within 24 hrs